---
title: "Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Clinical evidence"
description: "Formulary evidence on Lonvoguran ziclumeran (lonvo-z, NTLA-2002) in Hereditary angioedema: Clinical evidence. Covers HAELO, ITL-2002-CL-001, LTFU, HELP, OASIS-HAE, VANGUARD, and 2 further headings. 139 evidence topics quoted from 39 sources."
canonical: "https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 HAELO

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Trial objective

> “evaluate the efficacy and safety of NTLA-2002 compared to placebo”

Source: [Somatic Cell Gene Editing Consortium NCT06634420](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT06634420)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Registry locations

| Field | Reported value |
| --- | --- |
| Number of trial sites | “29” |
| Countries | “New Zealand,Canada,Netherlands,United States,South Africa,United Kingdom,Australia,France,Germany” |

Source: [Somatic Cell Gene Editing Consortium NCT06634420](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT06634420)

<a id="topic-3.1.1.2-2"></a>

###### First participant dosed: announcement date

> “January 22, 2025”

Source: [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

<a id="topic-3.1.1.2-3"></a>

###### Follow-up at the February 10, 2026 data cutoff

> “Median follow-up for enrolled patients: 7.5 months”

Source: [Intellia Therapeutics HAELO topline data presentation (2026)](https://ir.intelliatx.com/static-files/d76952d4-4a66-4ab1-b38d-4856721edea3)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Phase 3 HAELO: study design

> “randomized, double-blind, placebo-controlled”

Source: [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Registry inclusion criteria

> “Age ≥16 years”
> “Clinical history consistent with HAE-C1INH-Type 1 or -Type 2”
> “Must agree to follow contraception requirements”

Source: [Somatic Cell Gene Editing Consortium NCT06634420](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT06634420)

<a id="topic-3.1.1.4-2"></a>

###### Registry excluded HAE population

> “HAE with normal C1-INH”

Source: [Somatic Cell Gene Editing Consortium NCT06634420](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT06634420)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Phase 3 HAELO: randomization and dose

> “Patients will be randomized 2:1 to receive a single 50 mg infusion of NTLA-2002 or placebo.”

Source: [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

<a id="topic-3.1.1.5-2"></a>

###### Optional crossover for the placebo group

> “eligible for optional crossover to NTLA-2002 at week 28.”

Source: [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary clinical outcome: HAE attack frequency during weeks 5–28

> “number of HAE attacks”

Source: [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

<a id="topic-3.1.1.6.1-2"></a>

###### Validation of outcomes instruments: AE-QoL minimal clinically important difference

> “The MCID of the AE-QoL total score was found to be six points.”

Source: [Weller et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27038109/)

<a id="topic-3.1.1.6.1-3"></a>

###### Validation of outcomes instruments: AE-QoL content validation and psychometric evaluation

> “Patients agreed that the questionnaire items and response options were clear and relevant, and the 4-week recall period was appropriate.”

Source: [Vanya et al. (2023)](https://link.springer.com/article/10.1186/s41687-023-00576-w)

<a id="topic-3.1.1.6.1-4"></a>

###### Validation of outcomes instruments: AE-QoL content validation in adults and adolescents

> “Adolescents also reported that questions about school-related impacts were missing and would be important to ask about specifically.”

Source: [Broderick et al. (2025)](https://link.springer.com/article/10.1186/s41687-025-00876-3)

<a id="topic-3.1.1.6.1-5"></a>

###### Validation of outcomes instruments: AE-QoL psychometric validation

> “The AE-QoL demonstrated strong reliability, validity, and ability to detect change”

Source: [Feld et al. (2026)](https://link.springer.com/article/10.1186/s41687-026-01128-8)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Originally planned enrollment

> “60 adults”

Source: [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

<a id="topic-3.1.1.7.1-2"></a>

###### Registry actual enrollment

| Population | Participants |
| --- | --- |
| Enrolled | “80 (ACTUAL)” |

Source: [Somatic Cell Gene Editing Consortium NCT06634420](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT06634420)

Additional sources: [Cohn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42294842/)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Attack-rate model

> “Poisson regression model with Pearson Chi-square scaling of standard error”
> “treatment arm and baseline attack rate (> 3 vs ≤ 3 attacks/month)”

Source: [Intellia Therapeutics HAELO topline data presentation (2026)](https://ir.intelliatx.com/static-files/d76952d4-4a66-4ab1-b38d-4856721edea3)

<a id="topic-3.1.1.7.2-2"></a>

###### Analysis after initiation of long-term prophylaxis

> “attacks that started prior to prophylaxis initiation were included in the analysis.”

Source: [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Reported treatment groups

| Treatment | Participants |
| --- | --- |
| Lonvo-z | “n=52” |
| Placebo | “n=28” |

Source: [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Phase 3 baseline characteristics

| Characteristic | Lonvo-z, n=52 | Placebo, n=28 |
| --- | --- | --- |
| Age, median years (range) | “42 (23–71)” | “40 (19–76)” |
| Monthly attack rate during run-in, mean (SD) | “3.5 (1.8)” | “3.5 (1.9)” |

Source: [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Phase 3 HAELO: primary endpoint, weeks 5–28

> “a mean monthly attack rate of 0.26 in the lonvo-z arm compared with 2.10 in the placebo arm (p<0.0001).”

Source: [Intellia Therapeutics HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results)

<a id="topic-3.1.1.8.3-2"></a>

###### Phase 3 HAELO: relative attack-rate reduction

> “87% reduction”
> “(95% CI: 78%-93%)”

Source: [Intellia Therapeutics HAELO topline data presentation (2026)](https://ir.intelliatx.com/static-files/d76952d4-4a66-4ab1-b38d-4856721edea3)

<a id="topic-3.1.1.8.3-3"></a>

###### Phase 3 HAELO: attack-free status, weeks 5–28

| Lonvo-z | Placebo | Treatment comparison |
| --- | --- | --- |
| “62%” | “11%” | “Odds Ratio 12.8” “(95% CI: 3.5-47.6)” “p<0.0001” |

Source: [Intellia Therapeutics HAELO topline data presentation (2026)](https://ir.intelliatx.com/static-files/d76952d4-4a66-4ab1-b38d-4856721edea3)

<a id="topic-3.1.1.8.3-4"></a>

###### Phase 3 HAELO: additional attack-related secondary endpoints

| Endpoint | Reported treatment comparison |
| --- | --- |
| “attacks requiring on-demand treatment” | “89% reduction (79%, 94%), p<0.0001” |
| “moderate/severe attacks” | “91% reduction (81%, 96%), p<0.0001” |

Source: [Intellia Therapeutics additional HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Phase 3 HAELO: AE-QoL secondary endpoint

| Endpoint | Reported treatment comparison |
| --- | --- |
| “AE-QoL” | “-17.04 improvement (-24.15, -9.93), p<0.0001” |

Source: [Intellia Therapeutics additional HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3)

<a id="topic-3.1.1.8.4-2"></a>

###### Week 28 AE-QoL assessments

| Assessment | Lonvo-z | Placebo |
| --- | --- | --- |
| Participants with week 28 data | “n=44” | “n=20” |

Source: [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Phase 3 HAELO: safety through week 28

> “No serious TEAEs or Grade ≥3 TEAEs were reported in the lonvo-z arm”

Source: [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)

<a id="topic-3.1.1.8.5-2"></a>

###### Phase 3 HAELO: infusion-related reactions

| Event | Lonvo-z, n=52; n (%) | Placebo, n=28; n (%) |
| --- | --- | --- |
| “Infusion-related reaction” | “32 (62)” | “5 (18)” |

Source: [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)

<a id="topic-3.1.1.8.5-3"></a>

###### Phase 3 HAELO: infusion-related reaction severity and duration

> “mild or moderate”
> “transient”

Source: [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)

<a id="topic-3.1.1.8.5-4"></a>

###### Phase 3 HAELO: hepatic laboratory findings

> “single Grade 2 ALT elevation”
> “self-resolved in one week”

Source: [Intellia Therapeutics corporate overview (2026)](https://ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The randomized comparison enrolled 80 participants, with 52 receiving lonvo-z and 28 receiving placebo. Median follow-up was 7.5 months. This follow-up does not establish lifetime durability or exclude uncommon delayed adverse effects. Attack data after initiation of long-term prophylaxis were excluded from the reported attack-rate analysis. Week 28 AE-QoL data were available for 44 participants receiving lonvo-z and 20 receiving placebo, fewer than the randomized populations. The placebo-controlled design does not establish comparative effectiveness against an active prophylactic treatment. Eligibility excluded HAE with normal C1 inhibitor.

Source: [Somatic Cell Gene Editing Consortium NCT06634420](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT06634420); [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase); [Intellia Therapeutics HAELO topline data presentation (2026)](https://ir.intelliatx.com/static-files/d76952d4-4a66-4ab1-b38d-4856721edea3); [Intellia Therapeutics EAACI presentation (2026)](https://www.intelliatx.com/wp-content/uploads/HAELO-EAACI-2026-Presentation_FINAL.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 ITL-2002-CL-001

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Phase 1/2 registry objectives

> “evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002”

Source: [Somatic Cell Gene Editing Consortium NCT05120830](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT05120830)

<a id="topic-3.1.2.1-2"></a>

###### Phase 1 primary objectives

> “Evaluate safety and tolerability”

Source: [Intellia Therapeutics EAACI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/EAACI-2025_NTLA-Ph1-Durability_Oral_FINAL.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registry locations

| Field | Reported value |
| --- | --- |
| Number of trial sites | “9” |
| Countries | “New Zealand,Netherlands,United Kingdom,Australia,France,Germany” |

Source: [Somatic Cell Gene Editing Consortium NCT05120830](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT05120830)

<a id="topic-3.1.2.2-2"></a>

###### Phase 1 durability analysis: data cutoff

> “12 February 2025”

Source: [Intellia Therapeutics EAACI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/EAACI-2025_NTLA-Ph1-Durability_Oral_FINAL.pdf)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 1 design

> “Open-label, multicentre study in adults with HAE”

Source: [Intellia Therapeutics EAACI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/EAACI-2025_NTLA-Ph1-Durability_Oral_FINAL.pdf)

<a id="topic-3.1.2.3-2"></a>

###### Phase 2 study design

> “Double-blind, randomized”

Source: [Intellia Therapeutics ACAAI poster (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-Safety_Poster_FINAL.pdf)

<a id="topic-3.1.2.3-3"></a>

###### Phase 2 randomization

> “In this phase 2 portion of a phase 1-2 trial, we randomly assigned adults with hereditary angioedema in a 2:2:1 ratio to receive NTLA-2002 in a single dose of 25 mg or 50 mg or placebo.”

Source: [Cohn et al. (2025)](https://pure.amsterdamumc.nl/en/publications/crispr-based-therapy-for-hereditary-angioedema/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Phase 1/2 registry inclusion criteria

> “Age >18 years”
> “Diagnosis of HAE Types I or II”

Source: [Somatic Cell Gene Editing Consortium NCT05120830](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT05120830)

<a id="topic-3.1.2.4-2"></a>

###### Phase 1/2 registry exclusion criterion

> “Subjects who have known negative reaction or hypersensitivity to any lipid nanoparticles (LNP) component.”

Source: [Somatic Cell Gene Editing Consortium NCT05120830](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT05120830)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Phase 1 dose cohorts

| Cohort | Dose | Participants |
| --- | --- | --- |
| Lower dose | “25 mg” | “n=3” |
| Selected dose | “50 mg” | “n=4” |
| Higher dose | “75 mg” | “n=3” |

Source: [Intellia Therapeutics EAACI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/EAACI-2025_NTLA-Ph1-Durability_Oral_FINAL.pdf)

<a id="topic-3.1.2.5-2"></a>

###### Phase 2 treatment arms

> “single dose”
> “25 mg or 50 mg or placebo.”

Source: [Cohn et al. (2025)](https://pure.amsterdamumc.nl/en/publications/crispr-based-therapy-for-hereditary-angioedema/)

Additional sources: [Longhurst et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38294975/)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Phase 2 primary endpoint: weeks 1–16

> “number of angioedema attacks per month”

Source: [Cohn et al. (2025)](https://pure.amsterdamumc.nl/en/publications/crispr-based-therapy-for-hereditary-angioedema/)

<a id="topic-3.1.2.6.1-2"></a>

###### Pooled 50-mg analysis: composite outcome

> “attack-free and LTP-free from Week 5”

Source: [Banerji et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-New-Treatment-Goal-Poster_FINAL.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Registry actual enrollment across phases

| Population | Participants |
| --- | --- |
| Phase 1/2 | “37 (ACTUAL)” |

Source: [Somatic Cell Gene Editing Consortium NCT05120830](https://scge.mcw.edu/platform/data/report/clinicalTrials/NCT05120830)

<a id="topic-3.1.2.7.1-2"></a>

###### Phase 2 randomized and treated populations

| Population | Participants |
| --- | --- |
| Randomized | “27” |
| NTLA-2002 25 mg | “10” |
| NTLA-2002 50 mg | “11” |
| Placebo | “6” |

Source: [Cohn et al. (2025)](https://pure.amsterdamumc.nl/en/publications/crispr-based-therapy-for-hereditary-angioedema/)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Phase 2 attack-rate analysis

> “negative binomial model with treatment arm and baseline attack rate as independent variables.”

Source: [Intellia Therapeutics investor presentation (2024)](https://www.intelliatx.com/wp-content/uploads/Intellia_NTLA-2002-Phase-2-Data-Investor-Presentation_10.24.24_vF.pdf)

<a id="topic-3.1.2.7.2-2"></a>

###### Phase 2 paired AE-QoL analysis

> “Only patients with both baseline and Week 16 AE-QoL assessments were included in the analysis.”

Source: [Intellia Therapeutics AAAAI poster (2025)](https://www.intelliatx.com/wp-content/uploads/CRISPR-Based-NTLA-2002-Improves-Quality-of-Life-in-Patients-With-Hereditary-Angioedema.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Pooled 50-mg analysis: time origin

> “Data were analyzed from the time of 50 mg infusion”

Source: [Banerji et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-New-Treatment-Goal-Poster_FINAL.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Pooled 50-mg analysis population

| Population | Participants |
| --- | --- |
| Participants contributing to the pooled analysis | “32” |

Source: [Magerl et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-Durability-Update_Poster_FINAL-1.pdf)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Phase 2 baseline characteristics

| Characteristic | NTLA-2002 25 mg, n=10 | NTLA-2002 50 mg, n=11 | Placebo, n=6 |
| --- | --- | --- | --- |
| Age, median years (range) | “48.5 (34-62)” | “44.0 (18-61)” | “47.0 (31-76)” |
| Mean baseline monthly attack rate | “3.6” | “3.6” | “3.7” |

Source: [Intellia Therapeutics investor presentation (2024)](https://www.intelliatx.com/wp-content/uploads/Intellia_NTLA-2002-Phase-2-Data-Investor-Presentation_10.24.24_vF.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Phase 1 follow-up: EAACI 2025

> “Mean (SD) monthly attack rate during the on-study period was 0.09 (0.16) attacks/month”
> “All patients are attack-free and LTP-free”

Source: [Intellia Therapeutics EAACI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/EAACI-2025_NTLA-Ph1-Durability_Oral_FINAL.pdf)

<a id="topic-3.1.2.8.3-2"></a>

###### Phase 2: mean monthly attack rate, weeks 1–16

| Outcome | NTLA-2002 25 mg, n=10 | NTLA-2002 50 mg, n=11 | Placebo, n=6 |
| --- | --- | --- | --- |
| Mean monthly attack rate, weeks 1–16 | “0.70 (95% confidence interval [CI], 0.25 to 1.98)” | “0.65 (95% CI, 0.24 to 1.76)” | “2.82 (95% CI, 0.80 to 9.89)” |

Source: [Cohn et al. (2025)](https://pure.amsterdamumc.nl/en/publications/crispr-based-therapy-for-hereditary-angioedema/)

<a id="topic-3.1.2.8.3-3"></a>

###### Phase 2: difference versus placebo

| Outcome | NTLA-2002 25 mg | NTLA-2002 50 mg | Placebo |
| --- | --- | --- | --- |
| Difference versus placebo, weeks 1–16; 95% confidence interval | “−75% (-95%, 27%)” | “−77% (-95%, 15%)” |  |

Source: [Intellia Therapeutics investor presentation (2024)](https://www.intelliatx.com/wp-content/uploads/Intellia_NTLA-2002-Phase-2-Data-Investor-Presentation_10.24.24_vF.pdf)

<a id="topic-3.1.2.8.3-4"></a>

###### Phase 2: 50-mg group complete response

> “eight of 11 patients experienced a complete response”
> “no attacks at all during the 16-week primary observation period”

Source: [Intellia Therapeutics (2024)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-presents-positive-results-phase-2-study-ntla-2002)

<a id="topic-3.1.2.8.3-5"></a>

###### Pooled phase 1/2 and long-term follow-up: ACAAI 2025, August 29, 2025 data cutoff

> “24 patients have been attack-free and LTP-free for 7-32 months and remain so at last follow-up”

Source: [Intellia Therapeutics ACAAI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-50mg-and-LTFU_Oral_FINAL.pdf)

<a id="topic-3.1.2.8.3-6"></a>

###### Pooled phase 1/2 and long-term follow-up: median follow-up, AAAAI 2026

> “12.2 months (range: 2.4 months to 3.0 years)”

Source: [Magerl et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-Durability-Update_Poster_FINAL-1.pdf)

<a id="topic-3.1.2.8.3-7"></a>

###### Pooled phase 1/2 and long-term follow-up: attack-free status and prophylaxis, AAAAI 2026

> “Of the patients who became attack-free (31/32, 97%), all were also without LTP at the latest follow-up”

Source: [Magerl et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-Durability-Update_Poster_FINAL-1.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### Phase 2 patient-reported outcomes: AAAAI 2025

> “Patients who received NTLA-2002 50 mg experienced substantial improvements in all WPAI domains, especially in presenteeism and overall activity impairment”

Source: [Intellia Therapeutics AAAAI poster (2025)](https://www.intelliatx.com/wp-content/uploads/CRISPR-Based-NTLA-2002-Improves-Quality-of-Life-in-Patients-With-Hereditary-Angioedema.pdf)

<a id="topic-3.1.2.8.4-2"></a>

###### Phase 2 AE-QoL total score: change from baseline to week 16

| Outcome | NTLA-2002 25 mg, n=9 | NTLA-2002 50 mg, n=9 | Placebo, n=4 |
| --- | --- | --- | --- |
| Mean change ± SD | “-10.8 ±10.9” | “-18.2 ±17.2” | “-3.5 ±10.4” |

Source: [Intellia Therapeutics AAAAI poster (2025)](https://www.intelliatx.com/wp-content/uploads/CRISPR-Based-NTLA-2002-Improves-Quality-of-Life-in-Patients-With-Hereditary-Angioedema.pdf)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Phase 2 safety: October 2024 report

> “There have been no serious AEs”

Source: [Intellia Therapeutics (2024)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-presents-positive-results-phase-2-study-ntla-2002)

<a id="topic-3.1.2.8.5-2"></a>

###### Phase 2 safety: placebo-arm exception in the same report

> “one patient in the placebo arm who experienced a serious AE of Grade 4 edema of the tongue with breathing impairment”

Source: [Intellia Therapeutics (2024)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-presents-positive-results-phase-2-study-ntla-2002)

<a id="topic-3.1.2.8.5-3"></a>

###### Pooled phase 1/2 and long-term follow-up: serious pulmonary embolism

> “One serious AE of pulmonary embolism occurred in a patient with confounding risk factors”
> “the event resolved without sequelae”

Source: [Intellia Therapeutics ACAAI poster (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-Safety_Poster_FINAL.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

Phase 1 was open-label and included 10 participants across three dose cohorts. Phase 2 randomized 27 participants, including six assigned to placebo. The reported confidence intervals for the differences in monthly attack rate versus placebo crossed zero, so the point estimates alone do not demonstrate a statistically conclusive difference. The AE-QoL analysis included only participants with paired assessments and had nine, nine, and four participants in the 25-mg, 50-mg, and placebo groups, respectively. The pooled 50-mg analyses combine phase 1/2 and long-term follow-up observations. Becoming attack-free and prophylaxis-free during follow-up is not the same outcome as remaining attack-free throughout follow-up. Seven participants had less than six months of follow-up after becoming attack-free and prophylaxis-free. These pooled observations do not establish lifetime durability.

Source: [Intellia Therapeutics EAACI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/EAACI-2025_NTLA-Ph1-Durability_Oral_FINAL.pdf); [Cohn et al. (2025)](https://pure.amsterdamumc.nl/en/publications/crispr-based-therapy-for-hereditary-angioedema/); [Intellia Therapeutics investor presentation (2024)](https://www.intelliatx.com/wp-content/uploads/Intellia_NTLA-2002-Phase-2-Data-Investor-Presentation_10.24.24_vF.pdf); [Intellia Therapeutics AAAAI poster (2025)](https://www.intelliatx.com/wp-content/uploads/CRISPR-Based-NTLA-2002-Improves-Quality-of-Life-in-Patients-With-Hereditary-Angioedema.pdf); [Intellia Therapeutics ACAAI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-50mg-and-LTFU_Oral_FINAL.pdf); [Magerl et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-Durability-Update_Poster_FINAL-1.pdf); [Banerji et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-New-Treatment-Goal-Poster_FINAL.pdf)

<a id="topic-3.1.2.9-2"></a>

###### Pooled phase 1/2 and long-term follow-up: follow-up limitation

> “Follow-up time after becoming attack-free and LTP-free is limited for 7 patients (<6 months)”

Source: [Banerji et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-New-Treatment-Goal-Poster_FINAL.pdf)

Additional sources: [Jalal et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12688763/)

<a id="heading-3.1.3"></a>

#### 3.1.3 LTFU

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

No evidence found.

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Reported follow-up analysis: data cutoff

> “29 Aug 2025”

Source: [Intellia Therapeutics ACAAI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-50mg-and-LTFU_Oral_FINAL.pdf)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Subsequent long-term follow-up study

> “ongoing long-term follow-up (LTFU) study”

Source: [Banerji et al. (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_Lonvo-z-New-Treatment-Goal-Poster_FINAL.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Previous treatment before entry into long-term follow-up

> “lonvo-z 50 mg”

Source: [Intellia Therapeutics ACAAI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-50mg-and-LTFU_Oral_FINAL.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Long-term Safety as the Primary Endpoint

Not applicable.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Reported 50-mg long-term follow-up subgroup

> “n=17”

Source: [Intellia Therapeutics ACAAI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-50mg-and-LTFU_Oral_FINAL.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

Additional sources: [Intellia Therapeutics ACAAI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-50mg-and-LTFU_Oral_FINAL.pdf)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Safety in the 17-participant long-term follow-up subgroup

> “there were no SAEs or treatment-related AEs reported with lonvo-z 50 mg”

Source: [Intellia Therapeutics ACAAI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-50mg-and-LTFU_Oral_FINAL.pdf)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The separately identified long-term follow-up safety subgroup included 17 participants previously treated with 50 mg. The presentation reported no serious adverse events or treatment-related adverse events in that subgroup. The attack-free results in the same presentation combine parent-study and long-term follow-up observations and should not be interpreted as an independent 17-participant efficacy analysis. The subgroup size does not exclude uncommon delayed adverse effects.

Source: [Intellia Therapeutics ACAAI presentation (2025)](https://www.intelliatx.com/wp-content/uploads/ACAAI-2025_Lonvo-z-Ph1-2-50mg-and-LTFU_Oral_FINAL.pdf)

<a id="heading-3.1.4"></a>

#### 3.1.4 HELP

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Prevention objective

> “preventing hereditary angioedema attacks.”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study sites

> “41 sites”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Parallel-group design

> “randomized, double-blind, parallel-group, placebo-controlled”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Age eligibility

> “Patients aged ≥ 12 years”

Source: [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Subcutaneous lanadelumab regimens; placebo comparator

| Regimen | Dose and interval |
| --- | --- |
| Lower-dose monthly | “150 mg q4wks” |
| Higher-dose monthly | “300 mg q4wks” |
| Every two weeks | “300 mg q2wks” |

Source: [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary clinical endpoint

> “number of investigator-confirmed attacks of hereditary angioedema”

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Randomized treatment groups

| Group | Participants |
| --- | --- |
| Lanadelumab 150 mg every four weeks | “28” |
| Lanadelumab 300 mg every four weeks | “29” |
| Lanadelumab 300 mg every two weeks | “27” |
| Placebo | “41” |

Source: [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Primary analysis population and model

> “Intent-to-Treat”
> “Poisson regression model”

Source: [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Study completion

| Disposition | Participants, n (%) |
| --- | --- |
| Completed | “113 (90.4%)” |

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Age at baseline

| Characteristic | Reported value |
| --- | --- |
| Mean age, years | “40.7” |

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Mean monthly attack rate over 26 weeks

| Treatment | Attacks per month |
| --- | --- |
| Lanadelumab 150 mg every four weeks | “0.48” |
| Lanadelumab 300 mg every four weeks | “0.53” |
| Lanadelumab 300 mg every two weeks | “0.26” |
| Placebo | “1.97” |

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### Participants achieving the AE-QoL minimal clinically important difference

| Population | Proportion |
| --- | --- |
| All lanadelumab regimens pooled | “70%” |
| Placebo | “37%” |
| Lanadelumab 300 mg every two weeks | “81%” |

Source: [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Injection-site reactions

| Treatment | Participants, n (%) |
| --- | --- |
| Lanadelumab 150 mg every four weeks, n=28 | “16 (57)” |
| Lanadelumab 300 mg every four weeks, n=29 | “13 (45)” |
| Lanadelumab 300 mg every two weeks, n=27 | “15 (56)” |
| Placebo, n=41 | “14 (34)” |

Source: [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The randomized groups included 125 participants in total, and 113 (90.4%) completed the study. The 26-week placebo-controlled comparison describes repeated lanadelumab prophylaxis, not a comparison with lonvo-z. Differences between the trials in treatment schedules and observation periods prevent the reported attack rates from establishing comparative superiority.

Source: [Banerji et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583584/); [Lumry et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/all.14680); [FDA (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf); [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase); [Intellia Therapeutics HAELO phase 3 results announcement (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results)

<a id="heading-3.1.5"></a>

#### 3.1.5 OASIS-HAE

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Prophylaxis objective

> “prophylaxis to prevent attacks”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

No evidence found.

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Phase 3 design

> “double-blind, randomized”

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Age eligibility

> “12 years of age and older”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Dose, route, and dosing intervals

> “80 mg subcutaneously”
> “once every 4 or 8 weeks.”

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using HAE Attack Rate per Four Weeks as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary clinical endpoint: attack rate over the 24-week treatment period

> “HAE attacks per 4 weeks”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned enrollment

| Population | Participants |
| --- | --- |
| Planned total | “84” |

Source: [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)

<a id="topic-3.1.5.7.1-2"></a>

###### Actual treated populations

| Population | Participants |
| --- | --- |
| Donidalorsen every four weeks | “45” |
| Donidalorsen every eight weeks | “23” |
| Placebo | “22” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Full analysis set

> “all randomized patients who received at least 1 dose of Study Drug”

Source: [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)

<a id="topic-3.1.5.7.2-2"></a>

###### Primary count-data model

> “Poisson regression model and Pearson chi-square scaling of standard errors”

Source: [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Treatment exposure

| Population | Participants |
| --- | --- |
| Treated | “90” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Baseline demographics

| Characteristic | Reported value |
| --- | --- |
| Mean age, years (SD) | “37 (14)” |
| Female, n (%) | “48 (53)” |

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Mean attack rate per four weeks: weeks 1–25 in the publication

| Treatment | Attack rate |
| --- | --- |
| Donidalorsen every four weeks | “0.44” |
| Donidalorsen every eight weeks | “1.02” |
| Placebo | “2.26” |

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### AE-QoL improvement relative to placebo at week 25: every-four-week regimen

> “18.6 points (95% CI, 9.5 to 27.7)”

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Injection-site reactions

| Treatment | Participants, n (%) |
| --- | --- |
| Donidalorsen every four weeks, n=45 | “11 (24)” |
| Donidalorsen every eight weeks, n=23 | “1 (4)” |
| Placebo, n=22 | “1 (5)” |

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The study treated 90 participants, with 45 receiving donidalorsen every four weeks, 23 receiving it every eight weeks, and 22 receiving placebo. The full analysis set required at least one dose, rather than including every randomized participant regardless of exposure. The evidence describes a 24-week placebo-controlled comparison of repeated prophylaxis and does not directly compare donidalorsen with lonvo-z. The smaller every-eight-week and placebo groups limit precision for uncommon adverse events.

Source: [Riedl et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38819395/); [Ionis Pharmaceuticals protocol and statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/10/NCT05139810/Prot_SAP_000.pdf); [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.6"></a>

#### 3.1.6 VANGUARD

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Prophylactic treatment objective

> “prophylactic treatment for attacks due to hereditary angioedema (HAE).”

Source: [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Number of trial centers

> “28 centers”

Source: [FDA Drug Trials Snapshots ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Study design and allocation ratio

> “randomised, double-blind, placebo-controlled”
> “(3:2)”

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Eligibility: age and run-in attacks

> “12 years of age and older”
> “two or more acute HAE attacks”

Source: [FDA Drug Trials Snapshots ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Administration schedule

> “monthly subcutaneous injections of garadacimab”

Source: [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Primary endpoint: six-month observation

> “number of HAE attacks per month”

Source: [FDA Drug Trials Snapshots ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Randomized and included populations

| Population | Participants |
| --- | --- |
| Randomized | “65” |
| Garadacimab included | “39” |
| Placebo included | “25” |

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Safety population: minimum treatment exposure

> “at least one dose”

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Randomization error

> “One patient was randomly assigned in error”

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Baseline sex distribution

| Characteristic | Participants, n (%) |
| --- | --- |
| Female | “38 (59%)” |

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Published monthly attack rates and relative treatment effect

| Outcome | Reported value |
| --- | --- |
| Garadacimab: mean monthly attack rate | “0·27” |
| Placebo: mean monthly attack rate | “2·01” |
| Difference in means, percent | “-87%” |

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Nasopharyngitis adverse reactions

| Treatment | Participants, n (%) |
| --- | --- |
| Garadacimab, n=39 | “8 (21)” |
| Placebo, n=25 | “3 (12)” |

Source: [FDA Drug Trials Snapshots ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

Of 65 randomized participants, 64 were included in the reported comparison after one participant was randomized in error. The six-month trial compared monthly garadacimab with placebo, not with lonvo-z. Its group sizes of 39 and 25 participants limit precision for uncommon adverse events. The results should not be used as a head-to-head comparison with a one-time gene-editing treatment.

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/); [FDA Drug Trials Snapshots ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry); [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE); [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

<a id="heading-3.1.7"></a>

#### 3.1.7 APeX-2

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Treatment evaluation objective

> “efficacy, safety, and tolerability”

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Trial geography

> “40 sites in 11 countries”

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Study design

> “multicenter, randomized, double-blind, placebo-controlled, parallel-group study”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Run-in attack requirement

> “at least two investigator-confirmed attacks”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Berotralstat 110-mg and 150-mg regimens: route and administration

> “oral administration once daily, with food”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

Not applicable.

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Randomized and treated populations

| Population | Participants |
| --- | --- |
| Randomized | “121” |
| Berotralstat 110 mg treated | “41” |
| Berotralstat 150 mg treated | “40” |
| Placebo treated | “39” |

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Efficacy population and model

> “Intent-to-Treat (ITT) population”
> “negative binomial regression model”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

###### Treatment exposure

| Population | Participants |
| --- | --- |
| Received at least one dose | “120” |

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Median baseline attack rate during the prospective run-in period

> “2.9/month”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Monthly attack rates during the 24-week comparison

| Treatment | Attacks per month |
| --- | --- |
| Berotralstat 110 mg | “1.65” |
| Berotralstat 150 mg | “1.31” |
| Placebo | “2.35” |

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Serious treatment-emergent adverse events considered drug related

> “No drug-related serious treatment-emergent adverse events occurred.”

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

The study randomized 121 participants and treated 120. The efficacy population was intent-to-treat, whereas the reported treated populations included 41 participants receiving 110 mg, 40 receiving 150 mg, and 39 receiving placebo. The 24-week comparison evaluates ongoing oral prophylaxis and does not provide a direct comparison with lonvo-z. The absence of drug-related serious adverse events in this sample does not exclude uncommon risks.

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/); [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf); [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

<a id="heading-3.1.8"></a>

#### 3.1.8 COMPACT

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Clinical objective

> “clinical efficacy of SC CSL830 in the prophylactic treatment of HAE”

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Trial locations and global end date

| Field | Reported value |
| --- | --- |
| Planned region | “Argentina” |
| Planned region | “Australia” |
| Planned region | “Canada” |
| Planned region | “European Union” |
| Planned region | “United States” |
| Global end of trial | “2015-10-12” |

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Crossover design

> “32-week, multicenter, randomized, double-blind, placebo-controlled, crossover study”

Source: [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Age eligibility

> “12 years or older”

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Subcutaneous regimens and frequency

> “60 IU/kg”
> “40 IU/kg”
> “twice weekly (every 3 or 4 days)”

Source: [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using HAE Attack Frequency as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### Primary clinical endpoint

> “number of attacks of angioedema.”

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Planned enrollment

| Population | Participants |
| --- | --- |
| Whole trial | “100” |

Source: [EU Clinical Trials Register 2013-000916-10](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000916-10/ES)

<a id="topic-3.1.8.7.1-2"></a>

###### Actual randomization

| Population | Participants |
| --- | --- |
| Randomized | “90” |

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

###### Efficacy evaluation window

> “Efficacy was evaluated for the last 14 weeks of each treatment period.”

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

<a id="topic-3.1.8.8.1-1"></a>

###### Study completion

| Disposition | Participants |
| --- | --- |
| Completed | “79” |

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Baseline age

| Characteristic | Reported value |
| --- | --- |
| Median age, years (range) | “40 (12 to 72)” |

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Monthly attack-rate differences versus placebo

| Regimen | Mean difference, attacks per month |
| --- | --- |
| 40 IU/kg twice weekly | “-2.42” |
| 60 IU/kg twice weekly | “-3.51” |

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Most common adverse events

> “mild and transient local site reactions”

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

The crossover study randomized 90 participants, and 79 completed it. Efficacy was evaluated during the last 14 weeks of each treatment period, rather than the entire 32-week study. The findings concern repeated subcutaneous C1 inhibitor prophylaxis versus placebo within a crossover design. They do not establish comparative effectiveness against lonvo-z, which was evaluated in a parallel-group, single-infusion trial.

Source: [Longhurst et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28328347/); [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf); [CSL Behring (2026)](https://www.haegarda.com/hcp/efficacy); [Intellia Therapeutics HAELO first patient dosed announcement (2025)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-haelo-phase)

## Related pages
- [Lonvoguran ziclumeran (lonvo-z): Hereditary angioedema](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Terms and abbreviations](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/terms-and-abbreviations.md)
- [Lonvoguran ziclumeran (lonvo-z): Hereditary angioedema](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/executive-summary.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Product information and disease description](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/product-information-and-disease-description.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Economic information and modeling report](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/economics) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/economics.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: References](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/references) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/references.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: prevalence by geography](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/prevalence) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/prevalence.md)
- [Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/cost-effectiveness-analyses.md)
